These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

866 related items for PubMed ID: 16406064

  • 21. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 22. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, Schwartzberg L.
    Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629
    [Abstract] [Full Text] [Related]

  • 23. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ.
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [Abstract] [Full Text] [Related]

  • 24. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
    Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.
    Curr Med Res Opin; 2005 Oct; 21(10):1677-82. PubMed ID: 16238908
    [Abstract] [Full Text] [Related]

  • 25. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M, García Hernández MA, Navarro MJ, Pérez Silva F, Cacho M, De Gracia MC.
    Nefrologia; 2004 Oct; 24(1):54-9. PubMed ID: 15083958
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
    Charu V, Belani CP, Gill AN, Bhatt M, Tomita D, Rossi G, Ben-Jacob A.
    Oncologist; 2007 Jun; 12(6):727-37. PubMed ID: 17602062
    [Abstract] [Full Text] [Related]

  • 27. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G, Hurley D, Whyte JL, Willey V, Wilson M, Kallich J.
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [Abstract] [Full Text] [Related]

  • 28. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA, Walker R, Australian Renal Anaemia Group.
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [Abstract] [Full Text] [Related]

  • 29. Utilisation review of epoetin alfa in cancer patients at a cancer centre in Singapore.
    Chan A, Lim LL, Tao M.
    Singapore Med J; 2009 Apr; 50(4):365-70. PubMed ID: 19421679
    [Abstract] [Full Text] [Related]

  • 30. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice.
    Pujade-Lauraine E, Richard AJ, Sapède C, Hayward C.
    Oncol Rep; 2005 Oct; 14(4):1037-44. PubMed ID: 16142369
    [Abstract] [Full Text] [Related]

  • 31. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 32. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
    Prescrire Int; 2005 Oct; 14(79):174-6. PubMed ID: 16285072
    [Abstract] [Full Text] [Related]

  • 33. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.
    Glaspy JA, Tchekmedyian NS.
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):23-9. PubMed ID: 12435170
    [Abstract] [Full Text] [Related]

  • 34. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
    Boccia R, Lillie T, Tomita D, Balducci L.
    Oncologist; 2007 May; 12(5):584-93. PubMed ID: 17522247
    [Abstract] [Full Text] [Related]

  • 35. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.
    Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT.
    Clin Ther; 2006 Jun; 28(6):801-31. PubMed ID: 16860166
    [Abstract] [Full Text] [Related]

  • 36. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
    Littlewood TJ, Nortier J, Rapoport B, Pawlicki M, de Wasch G, Vercammen E, Schuette W, Wils J, Freund M, Epoetin Alfa Study Group.
    Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
    [Abstract] [Full Text] [Related]

  • 37. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
    Henry DH.
    Drugs; 2007 Dec; 67(2):175-94. PubMed ID: 17284083
    [Abstract] [Full Text] [Related]

  • 38. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
    Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP.
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):31-6. PubMed ID: 12435171
    [Abstract] [Full Text] [Related]

  • 39. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.
    Gordon D, Nichols G, Ben-Jacob A, Tomita D, Lillie T, Miller C.
    Oncologist; 2008 Jun; 13(6):715-24. PubMed ID: 18586927
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia.
    Bustos A, Álvarez R, Aramburo PM, Carabantes F, Díaz N, Florián J, Lázaro M, de Segovia JM, Gasquet JA, Alegre A, RADAR Study Group.
    Curr Med Res Opin; 2012 Jan; 28(1):57-67. PubMed ID: 22070513
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 44.